Dyne Therapeutics upgraded by Raymond James with a new price target
$DYN
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2025 | $40.00 | Perform → Outperform | Oppenheimer |
| 10/10/2025 | Outperform → Perform | Oppenheimer | |
| 8/25/2025 | $35.00 | Outperform → Strong Buy | Raymond James |
| 6/24/2025 | $13.00 | Mkt Perform | Bernstein |
| 6/11/2025 | $37.00 | Outperform | Raymond James |
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/29/2025 | $46.00 | Outperform | Evercore ISI |
| 3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
S-8 - Dyne Therapeutics, Inc. (0001818794) (Filer)
SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
Oppenheimer upgraded Dyne Therapeutics from Perform to Outperform and set a new price target of $40.00
Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform
Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts - - Two posters on myotonic dystrophy type 1 (DM1) focus on health insurance literacy and encore data from ACHIEVE clinical trial - WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that three poster presentations on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) will be prese
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes - - HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications - WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage com
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures - WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individua
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics. "We are pleased to welcome Vikram to our Board as we advance toward commercialization," said Jason
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose - - Functional improvement was observed across multiple clinical endpoints at 6 months in REC; lung function was preserved at 6 months - - New positive long-term results from DELIVER trial showed sustained functional improvement across all assessed endpoints through 24 months - - Continued favorable safety and tolerability profile - - Submission for U.S. Accelerated Approval on track for Q2 2026 - - Investor even
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and WebcastThe webcast will be available on the Events & Presentations page of the Investors & Medi
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically